Every Form 4 that Supernus Pharmaceuticals, Inc. (SUPN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SUPN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SUPN filings page.
SUPERNUS PHARMACEUTICALS, INC. reported that President and CEO Jack A. Khattar exercised 29,849 Performance Share Units into an equal number of shares of common stock on August 12, 2026. Of these shares, 12,642 were withheld to satisfy tax withholding requirements related to the vesting of the Performance Share Units. The remaining shares from this award increased his directly held common stock. A separate line shows 958,100 shares of common stock held indirectly by the KBT Trust. The Performance Share Units were originally awarded on February 19, 2025, and a portion vested upon achievement of individual performance objectives established on May 3, 2025.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief medical officer Jonathan Rubin reported equity award activity involving Performance Share Units and common stock. On August 12, 2026, 750 Performance Share Units were exercised and converted into 750 shares of common stock at a conversion price of $0.00 per share, following the achievement of individual performance objectives described in an award granted on February 19, 2025 and performance objectives established on May 3, 2025.
Of the common shares underlying this vesting, 363 shares of common stock were withheld by the company at a price of $46.57 per share to satisfy tax withholding requirements related to the vesting. Footnote disclosure also states that the reporting person’s direct holdings include an aggregate of 251 shares acquired through the issuer’s Employee Stock Purchase Plan.
SUPERNUS PHARMACEUTICALS, INC. executive Padmanabh P. Bhatt, Sr. VP of IP and CSO, reported equity compensation activity involving Performance Share Units. On August 12, 2026, he exercised 2,500 Performance Share Units, converting them into 2,500 shares of common stock.
On the same date, 1,158 common shares were disposed of at $46.57 per share, representing shares withheld by the company to satisfy tax withholding requirements related to the vesting of these Performance Share Units. After the exercise, no Performance Share Units from this award remained outstanding.
SUPERNUS PHARMACEUTICALS, INC. executive Frank Mottola, SVP and Chief Technical Operations Officer, exercised 1,650 Performance Share Units into an equal number of common shares on August 12, 2026. In connection with this vesting, 797 common shares were withheld by the company at $46.57 per share to satisfy tax withholding requirements. The performance share units were granted on February 19, 2025 and vested based on individual performance objectives established on May 3, 2025. Mottola’s common stock holdings include 251 shares acquired through the company’s Employee Stock Purchase Plan.
SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec exercised 1,250 Performance Share Units into 1,250 shares of common stock on August 12, 2026. The related derivative position was reduced to 0 units. Of the shares received, 604 shares were withheld by the company at $46.57 per share to satisfy tax withholding requirements tied to the vesting of these Performance Share Units. The filing also notes that Mr. Dec’s holdings include 251 shares acquired through the issuer’s Employee Stock Purchase Plan.
Supernus Pharmaceuticals reported that President and CEO Jack A. Khattar acquired 29,849 Performance Share Units on July 29, 2026, at $0.00 per unit. Each unit corresponds to one share of common stock, leaving him holding 29,849 such units from this award after the transaction.
The Performance Share Units were originally awarded on February 19, 2025, with a portion vesting upon the achievement of individual performance objectives that were established on May 3, 2025.
SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec acquired 1,250 Performance Share Units on July 29, 2026, representing 1,250 shares of common stock held directly at a per-unit price of $0.00. These units were originally awarded on February 19, 2025, with a portion vesting upon achievement of individual performance objectives set within a defined performance period and established on May 3, 2025.
Supernus Pharmaceuticals, Inc. executive Frank Mottola, SVP and Chief Technical Operations Officer, reported the acquisition of 1,650 Performance Share Units on July 29, 2026.
The units relate to an award granted on February 19, 2025 that vests upon achievement of individual performance objectives established on May 3, 2025. Following this transaction he holds 1,650 units directly, each corresponding to one share of common stock.
SUPERNUS PHARMACEUTICALS, INC. reported that Sr. VP of IP, CSO Padmanabh P. Bhatt acquired 2,500 Performance Share Units on July 29, 2026. These units, each tied to one share of Common Stock and granted at $0.00, relate to an award made on February 19, 2025 that vested upon achieving individual performance objectives established on May 3, 2025. Following this award, Bhatt holds 2,500 Performance Share Units directly.
SUPERNUS PHARMACEUTICALS, INC. reported that SVP and Chief Medical Officer Jonathan Rubin acquired 750 Performance Share Units on July 29, 2026. These units are a portion of an award granted on February 19, 2025 that vested upon achievement of individual performance objectives established on May 3, 2025 and are tied to 750 shares of common stock.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported a series of option exercises and share sales. Over March 16–18, 2026, he exercised employee stock options to acquire 107,250 shares of common stock at strike prices between $27.94 and $39.40 per share.
Across the same dates, he sold 107,250 common shares in open-market transactions at weighted-average prices within ranges from $49.34 to $51.15, with details available in the price footnotes. The filing notes that at least one transaction was made under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these transactions, Bhatt directly holds 17,044 Supernus shares.
SUPERNUS PHARMACEUTICALS, INC. President and CEO Jack A. Khattar reported trust-related stock activity in Supernus. On March 13, 2026, a trust associated with him, the KBT Trust, sold a total of 35,000 shares of common stock in open-market transactions at weighted average prices around $50–$52 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025.
On the same date, 12,500 shares were transferred from the KBT Trust to Khattar without consideration, moving from indirect to direct ownership. Following these changes, he held 1,241,144 shares directly and 958,100 shares indirectly through the KBT Trust, indicating a partial, planned reduction in the trust’s holdings while maintaining a substantial overall position.
SUPERNUS PHARMACEUTICALS, INC. director Frederick M. Hudson reported an open-market sale of 5,369 shares of Common Stock on March 12, 2026. The weighted average sale price was $50.6100 per share, with trades executed between $50.45 and $50.82. Following this transaction, he directly holds 60,413 shares.
Supernus Pharmaceuticals President and CEO Jack A. Khattar reported routine equity compensation activity involving Performance Share Units that converted into common stock. He exercised derivative awards covering 38,640 Performance Share Units, receiving the same number of shares of common stock.
To cover tax withholding triggered by this vesting, 16,574 shares of common stock were withheld by the company at $54.73 per share, as described in the footnotes. After these transactions, Khattar held 1,228,644 shares of common stock directly and 1,005,600 shares indirectly through the KBT Trust, reflecting a substantial ongoing ownership position.
Supernus Pharmaceuticals SVP Frank Mottola reported a combination of equity compensation events and a small stock sale. He exercised 3,750 Performance Share Units into common stock, with 1,793 shares withheld by the company to cover taxes upon vesting of those units. Shortly after, he executed an open‑market sale of 1,623 common shares at $53.65 per share. Following these transactions, he directly owns 18,440 shares of common stock, reflecting a routine use of vested equity and partial share sale.
SUPERNUS PHARMACEUTICALS, INC. Senior Vice-President & CFO Timothy C. Dec exercised performance share units and settled related taxes in stock. On March 6, 2026, he converted awards into 6,000 shares of common stock, with 2,883 shares withheld at $54.73 per share for tax obligations, leaving 8,232 shares held directly.
Supernus Pharmaceuticals SVP, Commercial Operations William Todd Horich reported a series of stock transactions involving performance-based awards and subsequent sales. On March 6, 2026, he exercised performance share units to acquire 7,500 shares of common stock at $0.00 per share. In connection with this vesting, the company withheld 3,455 shares at about $54.73 per share to cover tax obligations, as disclosed in the footnotes.
He then executed open-market sales of common stock, selling 4,438 shares at $54.00 on March 9 and 4,439 shares at $55.00 on March 10. After these transactions, his directly held common stock position reported in this filing was reduced to zero shares. The filing shows no remaining derivative holdings, indicating all reported performance share units tied to these transactions were fully settled.
Supernus Pharmaceuticals director Georges Gemayel reported an option exercise and related stock sales. On March 6, 2026, he exercised a director stock option for 7,905 shares, receiving common stock at an exercise price of $0.00 per share, and held 36,064 shares afterward.
He then sold 10,000 shares of common stock on March 5, 2026 at a weighted average price of about $53.71, and a further 8,787 shares on March 6, 2026 at about $53.00, in open-market transactions. After these sales, he directly owned 27,277 shares of Supernus common stock.
Supernus Pharmaceuticals President and CEO Jack A. Khattar reported the acquisition of 38,640 Performance Share Units at a price of $0.00 per unit. These units were awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives set on June 24, 2024.
SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec acquired performance share units. On the reported transaction date, 3,000 performance share units were credited to his direct holdings at no exercise price. According to a footnote, these units were originally awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives established on June 24, 2024.
SUPERNUS PHARMACEUTICALS, INC. reported an insider equity award for senior vice president and Chief Technology Operations Officer Frank Mottola. He acquired 3,750 Performance Share Units at a stated price of $0.00 per unit, leaving him with 3,750 such derivative securities held directly after the transaction.
According to the footnote, these Performance Share Units were originally awarded on February 23, 2023, with individual performance objectives for a defined performance period established on June 12, 2023. A portion of that award vested upon achievement of these objectives, and the reported acquisition reflects this vesting-based grant.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported routine equity compensation activity. On February 25, 2026, 1,875 restricted stock units were disposed of to the issuer and simultaneously settled into 1,875 shares of common stock as part of a vesting event.
In a separate transaction the same day, 977 shares of common stock were disposed of through a tax-withholding disposition at $50.69 per share to satisfy withholding obligations tied to the RSU vesting. After these transactions, Mottola directly owned 18,106 shares of common stock.
Supernus Pharmaceuticals Senior Vice-President & CFO Timothy C. Dec reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 25, 2,500 RSUs were settled into 2,500 shares of common stock, and 1,279 of those shares were withheld by the company to cover tax obligations at a price of $50.69 per share. After these transactions, Dec directly owned 5,115 shares of common stock. Each RSU represents one share of common stock and vests in four equal annual installments beginning on February 23, 2024.
SUPERNUS PHARMACEUTICALS, INC. Sr. VP of IP and CSO Padmanabh P. Bhatt reported equity award-related transactions. A grant of 1,250 shares of common stock was acquired at a price of $0.00, tied to restricted stock units that convert into one share each upon vesting.
On the same date, 1,250 restricted stock units were disposed back to the issuer and 650 shares of common stock at $50.69 were withheld by the company to cover tax obligations in connection with RSU vesting, rather than sold on the open market.
Supernus Pharmaceuticals executive Jonathan Rubin, SVP and Chief Medical Officer, reported equity award activity and related share transactions. He disposed of 1,250 restricted stock units back to the issuer and simultaneously acquired 1,250 shares of common stock at $0.00 per share as a grant. To cover taxes on the RSU vesting, 675 shares of common stock were automatically disposed of at $50.69 per share, with the company withholding these shares to satisfy tax obligations. Following these transactions, Rubin directly owned 13,341 shares of Supernus common stock.
SUPERNUS PHARMACEUTICALS, INC. Senior Vice-President & CFO Timothy C. Dec reported multiple equity compensation transactions on February 24, 2026. Restricted stock units were disposed back to the issuer as they vested, and related common stock was acquired. Some common shares were then delivered to cover tax withholding obligations at prices around $51 per share. Footnotes explain that each restricted stock unit converts into one common share and that various RSU grants vest in four equal annual installments beginning on February 19, 2026, February 22, 2023, and February 22, 2025.
SUPERNUS PHARMACEUTICALS, INC. director Charles W. Newhall III reported routine equity transactions. On February 24, 2026, 4,475 restricted stock units were disposed to the issuer and an equal 4,475 shares of common stock were acquired at no cost, bringing his direct holdings to 124,119 shares. Footnotes state each unit converts into one share, with vesting and settlement scheduled for February 19, 2026.
Supernus Pharmaceuticals director Frederick M. Hudson reported a routine equity award conversion. On February 24, 2026, 4,475 restricted stock units were disposed back to the issuer at no cost, and he simultaneously acquired 4,475 shares of common stock at no cost.
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting, with settlement in stock scheduled to occur on February 19, 2026. After these transactions, Hudson directly holds 65,782 shares of common stock, reflecting a shift from derivative RSU holdings into outright share ownership rather than an open-market purchase or sale.
SUPERNUS PHARMACEUTICALS, INC. director Carrolee Barlow reported routine equity award activity. On February 24, 2026, 4,475 restricted stock units were disposed of back to the company as they converted into 4,475 shares of common stock at no cash cost. After this grant/award acquisition, Barlow directly owns 27,045 shares of Supernus common stock.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Padmanabh P. Bhatt reported a series of equity-related transactions in connection with restricted stock units and common stock on February 24, 2026. He disposed of restricted stock units back to the issuer in amounts of 1,125, 750 and 1,250 units, each representing the right to receive one share of common stock upon vesting.
On the same date, he acquired common stock through grants or awards of 1,125, 750 and 1,250 shares. The filing also shows tax-withholding dispositions of 581, 354 and 646 common shares, with shares withheld by the company at prices of $51.35 and $50.86 per share to satisfy tax obligations upon RSU vesting. Certain RSUs vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025, and are settled in common stock.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported a mix of equity award activity and related share dispositions. On February 24, 2026, several restricted stock unit (RSU) awards vested, and RSUs totaling 1,125, 750 and 1,250 units were disposed of back to the company. Each RSU represents the right to receive one share of Supernus common stock upon vesting.
On the same date, Mottola received three common stock grants of 1,125, 750 and 1,250 shares at no cost, while 603, 368 and 670 common shares were delivered back to the company at prices of $51.35 and $50.86 to satisfy tax withholding obligations tied to the RSU vesting. The RSU awards vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025, as applicable.
SUPERNUS PHARMACEUTICALS SVP and Chief Medical Officer Jonathan Rubin reported multiple equity compensation events. On February 24, 2026, restricted stock units were disposed back to the company as they vested, and corresponding shares of common stock were acquired. Some of these new shares were withheld by the company to cover tax obligations. The RSUs each convert into one share of common stock and vest in four equal annual installments beginning on February 19, 2026, February 22, 2023, and February 22, 2025, depending on the grant.
SUPERNUS PHARMACEUTICALS, INC. director Georges Gemayel reported a mix of equity award activity and option exercises. On February 24, 2026, 4,475 restricted stock units were disposed of back to the issuer, while a matching 4,475 shares of common stock were acquired as a grant at no cost, bringing direct holdings in common stock to 38,159 shares.
On February 23, 2026, he exercised a director stock option for 15,000 shares of common stock at an exercise price of $12.98 per share, increasing his direct common stock ownership to 33,684 shares immediately after that exercise. Footnotes state each restricted stock unit represents one share of common stock and will settle in stock upon vesting on February 19, 2026.
SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig reported a set of stock transactions involving restricted stock units and common shares of SUPN. On February 19, 2026, she exercised 4,475 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share as the units vested.
That same day, she conducted open-market sales of common stock in two blocks: 1,217 shares at a weighted average price of $50.31 (with individual trades between $49.83 and $50.71) and 3,258 shares at a weighted average price of $51.27 (with trades between $50.98 and $51.56). These sales, totaling 4,475 shares, were made under a Rule 10b5-1 trading plan adopted on May 15, 2025, and left her with 0 shares of common stock directly owned after the reported transactions.
Supernus Pharmaceuticals reported that Senior Vice-President & CFO Timothy C. Dec received new equity awards. He was granted employee stock options for 17,500 shares at a price of $0.00 per share, which vest in four equal annual installments beginning on February 18, 2027. He also received 3,000 restricted stock units, each representing one share of common stock, vesting in four equal annual installments starting on the same date and settled in common stock upon vesting. Following these awards, he directly holds 1,638 shares of common stock, including an aggregate of 392 shares acquired through the company’s Employee Stock Purchase Plan.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported equity awards on February 18, 2026. He received an option to buy 13,500 shares of common stock and 3,000 restricted stock units, both granted at $0.00 per share as compensation.
The option and RSUs vest in four equal annual installments beginning on February 18, 2027. Following these awards, Bhatt directly holds 14,900 shares of common stock, which includes 392 shares acquired through the company’s employee stock purchase plan, along with the new option and RSU positions.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief medical officer Jonathan Rubin received new equity awards. On February 18, 2026, he was granted an employee stock option for 13,500 shares and 3,000 restricted stock units, both at no exercise cost per the filing.
The option vests in four equal annual installments starting February 18, 2027. Each restricted stock unit converts into one share of common stock and also vests in four equal annual installments beginning on that date. Following these awards, Rubin directly holds 11,284 shares of common stock, including 269 acquired through the employee stock purchase plan.
SUPERNUS PHARMACEUTICALS, INC. reported that SVP and Chief Technical Operations Officer Frank Mottola received new equity awards. He was granted employee stock options for 13,500 shares and 3,000 restricted stock units on February 18, 2026, both at a price of $0.00 per share.
The options vest in four equal annual installments beginning on February 18, 2027. Each restricted stock unit converts into one share of common stock and is settled in stock upon vesting, also in four equal annual installments starting on February 18, 2027. Following these grants, Mottola directly holds 15,724 shares of common stock, which include 228 shares acquired through the company’s employee stock purchase plan, along with the 13,500 options and 3,000 restricted stock units.
SUPERNUS PHARMACEUTICALS, INC. reported that President and CEO Jack A. Khattar received a grant of employee stock options for 341,610 shares on February 18, 2026. The options were awarded as a grant/award acquisition and vest in four equal annual installments beginning on February 18, 2027.
GEMAYEL GEORGES reported acquisition or exercise transactions in this Form 4 filing.
Supernus Pharmaceuticals director Georges Gemayel reported receiving new equity awards. On February 18, 2026, he was granted 2,989 restricted stock units and 4,977 director stock options, both at a price of $0.0000 per unit. The RSUs and options each vest on February 18, 2027.
Supernus Pharmaceuticals director Carrolee Barlow reported equity awards consisting of restricted stock units and stock options. On February 18, 2026, Barlow acquired 2,989 restricted stock units and 4,977 director stock options as compensation awards, with no cash paid per unit or option.
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. Both the restricted stock units and the options vest on February 18, 2027, at which time the restricted stock units will be settled in common stock and the options will become exercisable.
Sensenig Bethany reported acquisition or exercise transactions in this Form 4 filing.
SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig received new equity awards in the form of restricted stock units and stock options. She was granted 2,989 restricted stock units, each representing one share of Supernus common stock, and 4,977 director stock options.
The restricted stock units will be settled in common stock when they vest on February 18, 2027. The director stock options also vest on February 18, 2027. These awards increase Sensenig’s equity-based stake in the company but do not involve any open‑market share purchases or sales.
Supernus Pharmaceuticals director Charles W. Newhall III reported equity awards consisting of 2,989 restricted stock units and options for 4,977 shares, both granted on February 18, 2026. Each restricted stock unit converts into one share, and both the RSUs and options vest on February 18, 2027.
Hudson Frederick M. reported acquisition or exercise transactions in this Form 4 filing.
SUPERNUS PHARMACEUTICALS, INC. director Frederick M. Hudson reported equity awards consisting of restricted stock units and stock options. He was granted 2,989 restricted stock units and 4,977 director stock options on February 18, 2026, each at a grant price of $0 per unit or option.
Each restricted stock unit represents one share of Supernus common stock and will be settled in common stock when it vests on February 18, 2027. The stock options also vest on February 18, 2027, giving him the right to buy Supernus common stock in the future, subject to the option terms.
Supernus Pharmaceuticals director Hudson Frederick M. reported an option exercise and share acquisition. On January 9, 2026, he exercised a director stock option to buy 15,000 shares of common stock at an exercise price of $12.98 per share. The corresponding derivative position, a director stock option granted on March 1, 2017 and expiring on March 1, 2026, was reduced by 15,000 options to 0 following the transaction.
As a result of this option exercise, Hudson Frederick M. now directly owns 61,307 shares of Supernus Pharmaceuticals common stock. The filing classifies all reported holdings as directly owned, with no indirect ownership structures noted in the data provided.
A director of Supernus Pharmaceuticals, Inc. (SUPN) reported an option exercise and share acquisition. On 11/21/2025, the director exercised a Director Stock Option with an exercise price of $12.98 per share, acquiring 15,000 shares of common stock in a transaction coded "M" (option exercise). After this transaction, the director beneficially owned 119,644 shares of Supernus common stock in direct ownership form. The option originally covered 15,000 shares, was granted exercisable on 03/01/2017, and was set to expire on 03/01/2026; it now shows 0 derivative securities remaining following the reported exercise.
Supernus Pharmaceuticals (SUPN) senior officer reports equity award activity in a Form 4 filing. The Sr. VP of IP and Chief Scientific Officer reported a transaction dated 11/13/2025 involving derivative securities. The filing shows an acquisition of 1,500 Performance Share Units at an exercise price of $0, each linked to one share of common stock, leaving the officer with 1,500 derivative securities held directly. The non-derivative table indicates 13,718 shares of common stock beneficially owned directly following the reported transaction. An accompanying note explains that these Performance Share Units were originally awarded on February 22, 2022, with a portion vesting upon achievement of individual performance objectives set on May 3, 2022.
Insider transactions by the CEO/President and director Jack A. Khattar are reported on this Form 4. On 10/09/2025 Mr. Khattar exercised 81,250 employee stock options with an exercise price of $25.30 and immediately sold a total of 59,900 common shares in multiple transactions at weighted average prices of $50.55 and $51.46. After these transactions he directly beneficially owns 1,206,578 shares and indirectly holds 1,005,600 shares through the KBT Trust. The option grant vests in four equal installments that began on 02/24/2018.
Insider sale under 10b5-1 plan: A company director, Charles W. Newhall III, reported sales of a total of 25,000 shares of Supernus Pharmaceuticals, Inc. (SUPN) executed on 10/09/2025 under a trading plan adopted 03/03/2025. The sales are recorded as two blocks: 23,800 shares at a weighted average price of $50.73 and 1,200 shares at a weighted average price of $51.55, leaving beneficial ownership reported at 104,644 shares after the transactions.
The reporter certified the transactions were made pursuant to a Rule 10b5-1 plan and provided weighted-price ranges: $50.12–$51.08 for the larger block and $51.39–$51.76 for the smaller block. The Form 4 was signed by an attorney-in-fact on 10/10/2025.
Supernus Pharmaceuticals (SUPN) reported insider equity activity by its President, CEO and Director on 10/02/2025. The reporting person acquired 20,000 and 19,320 shares of common stock at $0 upon settlement of performance share units granted in 2021 and 2024. To cover taxes, the company withheld 7,796 and 7,529 shares at $46.21.
Following these transactions, the reporting person directly beneficially owned 1,185,228 shares. An additional 1,005,600 shares were beneficially owned indirectly via the KBT Trust. The performance share unit awards vested based on achievement of individual performance objectives set in 2021 and 2024.